Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Oral glibenklamid vid för tidig hyperglykemi (GALOP) (GALOP)

1 oktober 2026 uppdaterad av: Assistance Publique - Hôpitaux de Paris

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Studieöversikt

Detaljerad beskrivning

Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Studietyp

Interventionell

Inskrivning (Faktisk)

35

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Paris, Frankrike, 75015
        • Hopital Necker - Enfants malades

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 7 månader (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Newborn less than 34 week of amenorrhea corrected age
  • Birth weight < 1500 g
  • Birth term < 32 week of amenorrhea
  • Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
  • Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
  • Enteral feeding considered before inclusion or already established
  • Consent obtained from persons holding parental authority
  • Beneficiary of social security

Exclusion Criteria

  • Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
  • Contraindication to glibenclamide according to current SPC
  • Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
  • Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
  • Severe sepsis requiring mechanical ventilation or haemodynamic support
  • Severe renal dysfunction (serum creatinine > 120 µmol/l)
  • Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
  • Hyperglycemia associated with an error in administering glucose infusion
  • Profound hypophosphoremia (< 1 mmol/l)
  • Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
  • Patient with continuous insulin IV administration
  • Patient treated with miconazole

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Glibenclamide oral

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

  • For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);
  • For subsequent patients included during phase II:
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment
  • 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.
  • In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.

PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution.

blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized

If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Transaminases and hemostasis will be done only in case of clinical indication before the first administration.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Blood glucose control
Tidsram: At 72 hours after the first administration

The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours)

At 72 hours after the first administration

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall success of the treatment
Tidsram: At 36 week of amenorrhea corrected age

Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin.

At 36 week of amenorrhea corrected age
Blood glucose profile on glibenclamide
Tidsram: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Tidsram: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Tidsram: At the end of treatment assessed up to 15 days

Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Tidsram: At the end of treatment assessed up to 15 days

Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Tidsram: At the end of treatment assessed up to 15 days

Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Duration of glibenclamide treatment
Tidsram: At the end of treatment assessed up to 15 days

Duration of glibenclamide treatment.

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Tidsram: At the end of treatment assessed up to 15 days

Carbohydrate

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Tidsram: At the end of treatment assessed up to 15 days

lipid

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Tidsram: At the end of treatment assessed up to 15 days

protein

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Tidsram: At the end of treatment assessed up to 15 days

mean caloric intake (kcal/kg/day) during treatment

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Tidsram: At the end of treatment assessed up to 15 days

mean weight gain (g/kg/day)

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Tidsram: At 36 week of amenorrhea corrected age

Carbohydrate

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Tidsram: At 36 week of amenorrhea corrected age

lipid

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Tidsram: At 36 week of amenorrhea corrected age

protein

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Tidsram: At 36 week of amenorrhea corrected age

mean caloric intake (kcal/kg/day) during treatment

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Tidsram: At 36 week of amenorrhea corrected age

mean weight gain ((g/kg/day)

At 36 week of amenorrhea corrected age
Number of children with episode of hypoglycemia
Tidsram: At 72 hours after first administration

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At 72 hours after first administration
Number of children with episode of hypoglycemia
Tidsram: At the end of treatment assessed up to 15 days

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At the end of treatment assessed up to 15 days
Type of adverse reactions on glibenclamide
Tidsram: At 36 week of amenorrhea corrected age

evaluation of the type of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of adverse reactions on glibenclamide
Tidsram: At 36 week of amenorrhea corrected age

evaluation of number of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of participants with co-morbidity
Tidsram: At 36 week of amenorrhea corrected age

Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis

At 36 week of amenorrhea corrected age
Mortality
Tidsram: At 36 week of amenorrhea corrected age

Mortality will be assessed

At 36 week of amenorrhea corrected age
Dose adjustment
Tidsram: At the end of treatment assessed up to 15 days

Number of dose adjustments, to evaluate the easy of use

At the end of treatment assessed up to 15 days
ease of use by caregivers
Tidsram: At day one of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day one of treatment
ease of use by caregivers
Tidsram: At day two of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day two of treatment
ease of use by caregivers
Tidsram: At day three of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day three of treatment
Plasma concentrations of glibenclamide
Tidsram: At 3 hours after the first administration

Evaluated by the pharmacokinetics study

At 3 hours after the first administration
Plasma concentrations of glibenclamide
Tidsram: At 6 hours after the first administration

Evaluated by the pharmacokinetics study

At 6 hours after the first administration
Plasma concentrations of glibenclamide
Tidsram: At 10 hours after the first administration

Evaluated by the pharmacokinetics study

At 10 hours after the first administration
Plasma concentrations of glibenclamide
Tidsram: At 24 hours after the first administration

Evaluated by the pharmacokinetics study

At 24 hours after the first administration
Plasma concentrations of glibenclamide
Tidsram: At 24 hours of blood glucose stabilization

Evaluated by the pharmacokinetics study

At 24 hours of blood glucose stabilization

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
  • Studierektor: Michel POLAK, Assistance Publique - Hôpitaux de Paris
  • Studierektor: Delphine MITANCHEZ, CHRU de Tours

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 maj 2023

Primärt slutförande (Faktisk)

30 oktober 2025

Avslutad studie (Faktisk)

8 januari 2026

Studieregistreringsdatum

Först inskickad

7 december 2022

Först inskickad som uppfyllde QC-kriterierna

6 januari 2023

Första postat (Faktisk)

18 januari 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera